首页> 外文期刊>Brachytherapy >A dosimetric comparison of the Contura multilumen balloon breast brachytherapy catheter vs. the single-lumen MammoSite balloon device in patients treated with accelerated partial breast irradiation at a single institution
【24h】

A dosimetric comparison of the Contura multilumen balloon breast brachytherapy catheter vs. the single-lumen MammoSite balloon device in patients treated with accelerated partial breast irradiation at a single institution

机译:在一所机构接受局部乳腺加速照射的患者中,Contura多腔球囊乳房近距离放射治疗导管与单腔MammoSite球囊设备的剂量学比较

获取原文
获取原文并翻译 | 示例
           

摘要

A comparison of dosimetric findings in 33 patients treated with the Contura multilumen balloon (SenoRx Inc., Irvine, CA) (C-MLB) breast brachytherapy catheter vs. 33 patients treated with the MammoSite (Hologic Inc., Bedford, MA) (MS) at a single institution to deliver accelerated partial breast irradiation (APBI) was performed. Methods and Materials: CT-based 3-dimensional planning with dose optimization was completed. APBI treatment of 34. Gy in 3.4. Gy fractions was delivered. Endpoints analyzed included: (1) The percentage of the prescribed dose (PD) covering the planning target volume (PTV), (2) the maximum skin dose as a percentage of the PD, (3) the maximum rib dose as a percentage of the PD, and (4) the V150 and V200. Results: The C-MLB was placed more frequently in patients with closer skin spacing (<7 mm) and rib spacing (<7 mm) than in MS patients (45.5% vs. 12.1%, p= 0.0057 and 57.6 vs. 33.3, p= 0.0131, respectively). Despite closer skin spacing, the overall median skin dose was significantly lower in C-MLB patients (112% of the PD vs. 134%, p= 0.0282). No statistically significant differences in the V150 or V200 were observed. In patients with very limited rib spacing (<4 mm), the C-MLB delivered significantly lower rib doses than the MS (144% of the PD vs. 191%, p= 0.0107). In all clinical scenarios, coverage of the PTV with the C-MLB was either equal to or significantly better than with the MS (p= 0.0024). Conclusion: The C-MLB catheter produced clinically significant improvements in dosimetric endpoints (e.g., reduced skin and rib doses and improved PTV coverage) in most clinical scenarios.
机译:比较使用Contura多腔气囊(SenoRx Inc.,Irvine,CA)(C-MLB)乳房近距离放射导管治疗的33例患者与使用MammoSite(Hologic Inc.,Bedford,MA)治疗的33例患者的剂量学发现的比较)在单个机构进行,以提供加速的局部乳房照射(APBI)。方法和材料:完成了基于CT的3维计划,并进行了剂量优化。 APBI治疗34。Gy在3.4。递送Gy级分。分析的端点包括:(1)覆盖计划目标体积(PTV)的处方剂量(PD)的百分比,(2)最大皮肤剂量占PD的百分比,(3)最大肋骨剂量占以下指标的百分比PD,以及(4)V150和V200。结果:与MS患者相比,C-MLB放置在皮肤间距(<7 mm)和肋骨间距(<7 mm)更近的患者中更为频繁(45.5%vs. 12.1%,p = 0.0057和57.6 vs. 33.3, p分别为0.0131)。尽管皮肤间距更近,但C-MLB患者的总体中位皮肤剂量明显较低(PD的112%比134%,p = 0.0282)。在V150或V200中未观察到统计学上的显着差异。在肋骨间距非常有限(<4 mm)的患者中,C-MLB的肋骨剂量显着低于MS(PD的144%比191%,p = 0.0107)。在所有临床情况下,C-MLB对PTV的覆盖率均等于或明显优于MS(p = 0.0024)。结论:在大多数临床情况下,C-MLB导管在剂量学终点方面产生了临床上的显着改善(例如,减少了皮肤和肋骨的剂量并改善了PTV的覆盖范围)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号